Loading live market data…

Bayer AG

OTC:BAYRY

$13.6 USD

-$0.34 (-2.44%)

Volume
179.33K
Average Volume
1.43M
Market Capitalization
$53.44B
P/E Ratio
-21.79
Dividend Yield
0.23%
Price Target
$
Year High
$15.23
Year Low
$7.19
Day High
—
Day Low
—
Payout Ratio
$-0.06
Current Ratio
$1.06

Industry, Sector & symbol

Stock Exchange OTC
CEO William N. Anderson
Industry Drug Manufacturers - General
Sector Healthcare
Current Symbol BAYRY
CUSIP 072730302
CIK None
Web https://www.bayer.com
Phone 49 214 30 1
Currency USD
Employees 90587
Country DE

Liquidity

Debt-to-Equity Ratio 1.35
Payout Ratio -0.06
Current Ratio 1.06
Quick Ratio 0.70
Cash Ratio 0.17

Sales & Book Value

Annual Sales $43.78B
Price / Sales 1.04
Cash Flow 0.51
Price / Cash Flow 23.28
Price / Book 1.62

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 3 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.88
Trailing P/E Ratio -21.79
PEG Ratio 0.01
P/E Growth 0.01
Net Income $-3.48B
Net Margin -4.77%
Pretax Margin -4.35%
Return on Equity -7.52%
Return on Assets -2.00%

Financials Score

AltmanZ Score 0.95
Piotroski Score 4.00
Working Capital 1.84B
Total Assets 108.06B
Ebit 4.41B
Market Cap 48.86B
Total Liabilities 79.06B

Poll Results

About Bayer AG (OTC:BAYRY) Stock

Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products ad ... dress diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.

Bayer: Debt Remains A Problem, Value Remains Compelling

2026-07-13 09:38:56

Bayer Aktiengesellschaft remains undervalued despite a strong 18-month rally and ongoing operational improvements. I see upside potential supported by improving EBIT, robust pipeline assets, and technical breakout, though litigation and high debt persist. Litigation settlements and negative free cash flow weigh on the balance sheet, but recent Apollo investment and restructuring efforts provide some relief.

Apollo to Buy $3.4 Billion Stake in Bayer Contraceptives Business

2026-07-10 02:45:00

The asset-management firm agreed to buy a minority stake in Bayer's long-acting reversible contraceptives business.

Bayer gets €3 billion in Apollo deal for contraceptives unit

2026-07-10 02:33:42

Bayer said on Friday it had secured €3 ​billion ($3.4 billion) in equity from ‌Apollo-managed funds in a deal tied to its long-acting reversible contraceptives, or LARC, business, ​aiming to bolster its capital ​structure while preserving control.

Bayer seeks US duties on Chinese-made glyphosate, angering farmers

2026-06-30 20:24:00

June 30 (Reuters) - Bayer asked ​Washington to impose duties on glyphosate, the chemical used in the company's weedkiller Roundup, ‌imported from China, saying it was being sold at artificially low prices.

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

2026-06-30 07:45:03

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

BAYRY Stock Surges 17% After Supreme Court Roundup Ruling

2026-06-26 11:06:08

Bayer shares jump 17% after a Supreme Court ruling on Roundup litigation that could significantly reduce warning-based claims and litigation costs.

Bayer Gets New Life After Supreme Court's Roundup Ruling

2026-06-26 10:00:00

A high-court victory gives the German company more leverage to settle outstanding cases.

Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?

2026-06-26 09:45:34

Bayer (BAYRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Frequently Asked Questions

What is the current Bayer AG (BAYRY) stock price?

Bayer AG(OTC:BAYRY) stock price is $13.6 in the last trading session. During the trading session, BAYRY stock reached the peak price of $15.23 while $7.19 was the lowest point it dropped to. The percentage change in BAYRY stock occurred in the recent session was --2.44% while the dollar amount for the price change in BAYRY stock was -$-0.34.

BAYRY's industry and sector of operation?

The OTC listed BAYRY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of BAYRY?

Stefan Oelrich | President of the Pharmaceuticals Division & Member of the Board of Management
Judith Hartmann | Chief Financial Officer & Member of Management Board
Wolfgang U. Nickl | Chief Financial Officer & Member of Management Board
Bill Dodero | General Counsel and Senior Vice President of Law Patents & Compliance
Julio Triana | Member of Management Board & President of Consumer Health Division

How many employees does BAYRY have?

Number of BAYRY employees currently stands at 90587. BAYRY operates from Kaiser-Wilhelm-Allee 1, Leverkusen, NW 51368, DE.

Link for BAYRY official website?

Official Website of BAYRY is: https://www.bayer.com

How do I contact BAYRY?

BAYRY could be contacted at phone #49 214 30 1 and can also be accessed through its website. BAYRY operates from Kaiser-Wilhelm-Allee 1, Leverkusen, NW 51368, DE.

How many shares of BAYRY are traded daily?

The average number of BAYRY shares traded daily for last 3 months was 1.43M.

What is the market cap of BAYRY currently?

The market value of BAYRY currently stands at $53.44B with its latest stock price at $13.6